Associated Papers
Diosgenin reduces β-sheet content in mutated α-syn aggregation: Insights from conformational dynamics at intracellular and extracellular neuronal salt concentrations.
Nandeshwar et al.
Journal of Molecular Graphics & Modelling, 2026
Parkinson's disease-associated mutations in α-synuclein alters its lipid-bound state.
Maltseva S et al.
Biophysical Journal, 2024
Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping.
Ndayisaba A et al.
Cerebellum (london, England), 2024
α-Synuclein-dependent increases in PIP5K1γ drive inositol signaling to promote neurotoxicity.
Horvath JD et al.
Cell Reports, 2023
Chemical Synthesis of Alpha-Synuclein Proteins via Solid-Phase Peptide Synthesis and Native Chemical Ligation.
Gatzemeier LM et al.
Chemistry (weinheim an Der Bergstrasse, Germany), 2023
Interfacial properties of α-synuclein's Parkinsonian variants.
Mohapatra A et al.
Biophysical Chemistry, 2023
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
Effects of Mutations and Post-Translational Modifications on α-Synuclein In Vitro Aggregation.
Pancoe SX et al.
Journal of Molecular Biology, 2022
Generation of an induced pluripotent stem cell line (EURACi014-A) from a Parkinson's disease patient with an A53T mutation in the SNCA gene by an integration-free reprogramming method.
Gilmozzi V et al.
Stem Cell Research, 2022
Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
Padilla-Godínez FJ et al.
International Journal of Molecular Sciences, 2021
Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
Castonguay AM et al.
Journal of Parkinson's Disease, 2021
New insights on the structure of alpha-synuclein fibrils using cryo-electron microscopy.
Guerrero-Ferreira R et al.
Current Opinion in Neurobiology, 2020
Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson's disease.
Feng ST et al.
Pharmacological Research, 2020
Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by α-Synuclein.
Cuddy LK et al.
Neuron, 2019
Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
Ruf VC et al.
Acs Chemical Neuroscience, 2019
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA et al.
Acs Chemical Neuroscience, 2019
Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O et al.
International Journal of Molecular Sciences, 2018
α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton.
Ordonez DG et al.
Neuron, 2018
Extracellular α-synuclein induces sphingosine 1-phosphate receptor subtype 1 uncoupled from inhibitory G-protein leaving β-arrestin signal intact.
Zhang L et al.
Scientific Reports, 2017
Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.
Ottolini D et al.
Biological Chemistry, 2017
Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients.
Kröner C et al.
The European Respiratory Journal, 2015
Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein.
Sahay S et al.
The Journal of Biological Chemistry, 2015
Genetic variants and animal models in SNCA and Parkinson disease.
Deng H et al.
Ageing Research Reviews, 2014
Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Bodner CR et al.
Biochemistry, 2010
Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S et al.
Biochemical and Biophysical Research Communications, 2009
Novel suppressors of alpha-synuclein toxicity identified using yeast.
Liang J et al.
Human Molecular Genetics, 2008
Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.
Yu WH et al.
Neurochemical Research, 2008
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
Kahle PJ
Acta Neuropathologica, 2008
YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation.
Flower TR et al.
The Journal of Cell Biology, 2007
alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis.
Jo E et al.
European Journal of Biochemistry, 2004
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
Dev KK et al.
Neuropharmacology, 2003
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T et al.
Neurobiology of Aging, 0